MEA Acute Respiratory Distress Syndrome (ARDS) Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 41
1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW OF MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 41
1.4 LIMITATIONS 43
1.5 MARKETS COVERED 43
2 MARKET SEGMENTATION 46
2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 CURRENCY AND PRICING 48
2.5 DBMR TRIPOD DATA VALIDATION MODEL 49
2.6 MULTIVARIATE MODELLING 52
2.7 CAUSE LIFELINE CURVE 53
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 54
2.9 DBMR MARKET POSITION GRID 55
2.10 MARKET END USER COVERAGE GRID 56
2.11 VENDOR SHARE ANALYSIS 57
2.12 SECONDARY SOURCES 58
2.13 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 62
4.1 PESTEL ANALYSIS 64
4.2 PORTERS FIVE FORCES 65
5 MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: REGULATIONS 66
5.1 REGULATION IN U.S.: 66
5.2 REGULATION FOR VENTILATORS AND RESPIRATORY DEVICES AS PER FDA 67
5.3 REGULATION FOR THE USE OF VENTILATOR AND ANESTHESIA GAS MACHINE BREATHING CIRCUIT DEVICES 68
5.4 LABELING OF MODIFIED DEVICES 68
5.5 REGULATION IN EUROPE: 69
5.6 REGULATION IN INDIA: 70
5.7 REGULATION IN JAPAN: 71
6 REGIONAL SUMMARY 72
6.1 NORTH AMERICA REGION 72
6.2 EUROPE REGION 73
6.3 ASIA-PACIFIC 73
6.4 SOUTH AMERICA 74
6.5 MIDDLE EAST AND AFRICA 74
7 PIPELINE ANALYSIS 75
8 INSURANCE REIMBURSEMENT 77
8.1 CENTER FOR MEDICARE SERVICES (CMS)ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 77
8.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 78
8.3 ABBOTT CODING GUIDE FOR ECMO 78
8.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 79
8.5 CERN HEALTH INSURANCE SCHEME 79
8.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)  (MEDICARE & MEDICAID) 79
8.7 AMERICAN HOSPITAL ASSOCIATION 80
8.8 CONCLUSION 80
9 MARKET OVERVIEW 81
9.1 DRIVERS 83
9.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 83
9.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS 83
9.1.3 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS 84
9.1.4 RISING RATE OF AIR POLLUTION AND LIFESTYLE-RELATED DISEASES 84
9.1.5 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 85
9.2 RESTRAINTS 85
9.2.1 COMPLICATIONS ASSOCIATED WITH TREATMENTS 85
9.2.2 HIGH COST OF DEVICE AND TREATMENTS 86
9.2.3 LACK OF SKILLED WORKFORCE 86
9.3 OPPORTUNITIES 87
9.3.1 GROWING GERIATRIC POPULATION 87
9.3.2 RISING HEALTHCARE EXPENDITURE 88
9.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 88
9.3.4 IMPROVING AWARENESS REGARDING ARD SYNDROME 89
9.4 CHALLENGES 90
9.4.1 STRINGENT RULES & REGULATIONS 90
9.4.2 MULTIPLE CHALLENGES FACED BY ICU NURSES 90
10 IMPACT OF COVID-19 PANDEMIC ON THE MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 92
10.1 PRICE IMPACT 92
10.2 IMPACT ON DEMAND 93
10.3 IMPACT ON SUPPLY CHAIN 94
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS 94
10.5 CONCLUSION 95
11 MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE 96
11.1 OVERVIEW 97
11.2 DIAGNOSIS 100
11.2.1 IMAGING TESTS 100
11.2.1.1 CHEST X-RAY 101
11.2.1.2 CT SCAN 101
11.2.1.3 ULTRASOUND 101
11.2.1.4 OTHERS 101
11.2.2 BLOOD TEST 101
11.2.3 RESPIRATORY RATE 101
11.2.4 SPO2 TEST 101
11.2.5 OTHERS 102
11.3 TREATMENT 102
11.3.1 MECHANICAL VENTILATION 103
11.3.1.1 HIGH-FLOW NASAL O2 103
11.3.1.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 103
11.3.1.3 CONTINOUS POSITIVE AIRWAY PRESSURE 103
11.3.1.4 PRONE POSITIVE VENTILATION 103
11.3.1.5 OTHERS 103
11.3.2 CORTICOSTEROIDS 104
11.3.2.1 METHYLPREDNISOLONE 104
11.3.2.2 DEXAMETHASONE 104
11.3.2.3 OTHERS 104
11.3.3 ANTIVIRAL MEDICATION 105
11.3.3.1 REMDESIVIR 105
11.3.3.2 COMBINATION DRUGS 105
11.3.3.3 OTHERS 105
11.3.4 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 105
11.3.5 TOCILIZUMAB 105
11.3.6 OTHERS 105
12 MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION 106
12.1 OVERVIEW 107
12.2 PARENTERAL 110
12.2.1 INTRAVENOUS 110
12.2.2 INTRAMUSCULAR 110
12.3 ORAL 111
12.4 OTHERS 111
13 MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE 112
13.1 OVERVIEW 113
13.2 CORONAVIRUS DISEASE 2019 (COVID-19) 116
13.3 SEPSIS 116
13.4 INHALATION OF HARMFUL SUBSTANCES 117
13.5 SEVERE PNEUMONIA 117
13.6 OTHERS 118
14 MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER 119
14.1 OVERVIEW 120
14.2 HOSPITALS 123
14.3 SPECIALTY CLINICS 123
14.4 HOME HEALTHCARE 124
14.5 OTHERS 124
15 MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL 125
15.1 OVERVIEW 126
15.2 DIRECT TENDER 129
15.3 HOSPITAL PHARMACY 129
15.4 RETAIL PHARMACY 130
15.5 ONLINE PHARMACY 130

16 MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION 131
16.1 MIDDLE EAST AND AFRICA 132
16.1.1 SOUTH AFRICA 141
16.1.2 SAUDI ARABIA 145
16.1.3 UAE 149
16.1.4 ISRAEL 153
16.1.5 EGYPT 157
16.1.6 KUWAIT 161
16.1.7 REST OF MIDDLE EAST AND AFRICA 165
17 MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY LANDSCAPE 166
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 166
18 SWOT ANALYSIS 167
19 COMPANY PROFILE 168
19.1 GILEAD SCIENCES INC. 168
19.1.1 COMPANY SNAPSHOT 168
19.1.2 REVENUS ANALYSIS 168
19.1.3 COMPANY SHARE ANALYSIS 169
19.1.4 PRODUCT PORTFOLIO 169
19.1.5 RECENT DEVELOPMENT 169
19.2 TERUMO CORPORATION 170
19.2.1 COMPANY SNAPSHOT 170
19.2.2 REVENUS ANALYSIS 170
19.2.3 COMPANY SHARE ANALYSIS 171
19.2.4 PRODUCT PORTFOLIO 171
19.2.5 RECENT DEVELOPMENT 171
19.3 GETINGE AB 172
19.3.1 COMPANY SNAPSHOT 172
19.3.2 REVENUS ANALYSIS 172
19.3.3 COMPANY SHARE ANALYSIS 173
19.3.4 PRODUCT PORTFOLIO 173
19.3.5 RECENT DEVELOPMENT 173

19.4 LIVANOVA PLC 174
19.4.1 COMPANY SNAPSHOT 174
19.4.2 REVENUE ANALYSIS 174
19.4.3 COMPANY SHARE ANALYSIS 175
19.4.4 PRODUCT PORTFOLIO 175
19.4.5 RECENT DEVELOPMENTS 175
19.5 MEDTRONIC 176
19.5.1 COMPANY SNAPSHOT 176
19.5.2 REVENUE ANALYSIS 176
19.5.3 COMPANY SHARE ANALYSIS 177
19.5.4 PRODUCT PORTFOLIO 177
19.5.5 RECENT DEVELOPMENTS 177
19.6 ALUNG TECHNOLOGIES, INC 178
19.6.1 COMPANY SNAPSHOT 178
19.6.2 PRODUCT PORTFOLIO 178
19.6.3 RECENT DEVELOPMENT 178
19.7 ARMSTRONG MEDICAL 179
19.7.1 COMPANY SNAPSHOT 179
19.7.2 PRODUCT PORTFOLIO 179
19.7.3 RECENT DEVELOPMENT 179
19.8 BESMED HEALTH BUSINESS CORP. 180
19.8.1 COMPANY SNAPSHOT 180
19.8.2 PRODUCT PORTFOLIO 180
19.8.3 RECENT DEVELOPMENTS 181
19.9 DRGERWERK AG & CO. KGAA 182
19.9.1 COMPANY SNAPSHOT 182
19.9.2 REVENUE ANALYSIS 182
19.9.3 PRODUCT PORTFOLIO 183
19.9.4 RECENT DEVELOPMENTS 183
19.10 EUROSETS 184
19.10.1 COMPANY SNAPSHOT 184
19.10.2 PRODUCT PORTFOLIO 184
19.10.3 RECENT DEVELOPMENT 184
19.11 F. HOFFMANN-LA ROCHE LTD 185
19.11.1 COMPANY SNAPSHOT 185
19.11.2 RECENT ANALYSIS 185
19.11.3 PRODUCT PORTFOLIO 186
19.11.4 RECENT DEVELOPMENTS 186

19.12 FISHER & PAYKEL HEALTHCARE LIMITED 187
19.12.1 COMPANY SNAPSHOT 187
19.12.2 REVENUE ANALYSIS 187
19.12.3 PRODUCT PORTFOLIO 188
19.12.4 RECENT DEVELOPMENTS 188
19.13 FRESENIUS SE & CO. KGAA 189
19.13.1 COMPANY SNAPSHOT 189
19.13.2 REVENUS ANALYSIS 189
19.13.3 PRODUCT PORTFOLIO 190
19.13.4 RECENT DEVELOPMENTS 190
19.14 HAMILTON MEDICAL 191
19.14.1 COMPANY SNAPSHOT 191
19.14.2 PRODUCT PORTFOLIO 191
19.14.3 RECENT DEVELOPMENT 191
19.15 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 192
19.15.1 COMPANY SNAPSHOT 192
19.15.2 PRODUCT PORTFOLIO 192
19.15.3 RECENT DEVELOPMENT 193
19.16 NIPRO 194
19.16.1 COMPANY SNAPSHOT 194
19.16.2 REVENUS ANALYSIS 194
19.16.3 PRODUCT PORTFOLIO 195
19.16.4 RECENT DEVELOPMENT 195
19.17 PFIZER INC. 196
19.17.1 COMPANY SNAPSHOT 196
19.17.2 REVENUS ANALYSIS 196
19.17.3 PRODUCT PORTFOLIO 197
19.17.4 RECENT DEVELOPMENT 197
19.18 RESMED 198
19.18.1 COMPANY SNAPSHOT 198
19.18.2 REVENUE ANALYSIS 198
19.18.3 PRODUCT PORTFOLIO 199
19.18.4 RECENT DEVELOPMENT 199
19.19 SMITHS MEDICAL 200
19.19.1 COMPANY SNAPSHOT 200
19.19.2 REVENUS ANALYSIS 200
19.19.3 PRODUCT PORTFOLIO 201
19.19.4 RECENT DEVELOPMENTS 201

19.20 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 202
19.20.1 COMPANY SNAPSHOT 202
19.20.2 PRODUCT PORTFOLIO 202
19.20.3 RECENT DEVELOPMENT 202
20 QUESTIONNAIRE 203
21 RELATED REPORTS 207